Cross Infection

• EMA withdrawal · 2018-05-16
  EMA Withdrawn: Vibativ (telavancin) — Theravance Biopharma Ireland Umited

  The EMA has withdrawn Vibativ (telavancin) from the market in the EU, a drug indicated for bacterial pneumonia and cross-infection.

• EMA withdrawal · 2014-10-17
  EMA Withdrawn: Doribax (doripenem) — Janssen-Cilag International NV

  Doribax (doripenem) has been withdrawn from the European market by Janssen-Cilag International NV due to regulatory decision.

• CLINICAL_TRIALS trial_result · 2010-05-25
  Clinical Trial Update: Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections [Phase 4]

  Phase 4 clinical trial evaluating intranasal mupirocin for prevention of Staphylococcus aureus infections; study completed.

• CLINICAL_TRIALS trial_result · 2006-07-18
  Clinical Trial Update: Computerized Decision Support System for Antibiotic Treatment [Phase 3]

  A Phase 3 trial evaluating a computerized decision support system for guiding antibiotic treatment has completed.